News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Novartis AG Says FDA Wants New Galvus Study; Shares Drop
February 26, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Feb 26 (Reuters) - U.S. regulators are unlikely to request a long-term clinical study on Novartis AG's diabetes drug Galvus, the company said on Monday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Tariffs
Trump Threatens 200% Pharma Tariffs—But Gives At Least 1-Year Grace Period
July 9, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
·
1 min read
·
Heather McKenzie
Government
Trump’s Tax Law Restores Orphan Drug Exemptions, Cuts Medicaid, Threatens 340B Program and Gives PBMs a Pass
July 8, 2025
·
3 min read
·
Tristan Manalac
